Skip to main content

Table 2 Univariate Cox proportional hazard analysis

From: Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients

VariableOverall survivalRelapse-free survival
HR (95% Cl)pHR (95% Cl)p
CA1251 (1–1)0.141 (1–1)0.31
Stage 0.55 0.8
 Stage I1 1 
 Stage II0.61 (0.12–3.14]0.521.14 (0.4–3.19)0.808
 Stage III2.99 (1.21–7.43]0.0182.64 (1.33–5.26)0.006
 Stage IV5.35 (1.63–17.57)0.0064.84 (1.79–13.09)0.002
Debulking 0.22 0.08
 Debulking R01 1 
 Debulking R11.67 (0.73–3.8)0.2241.84 (0.92–3.67)0.084
 Debulking R22.17 (1.36–3.47)0.0012.76 (1.85–4.13)< 0.0001
Age1 (0.98–1)0.731 (0.99–1)0.48
CALR0.96 (0.94–0.98)< 0.00010.97 (0.95–0.98)< 0.0001
DC-LAMP summary0.86 (0.76–0.96)0.00970.98 (0.94–1)0.19
CD8 summary1 (1–1)0.0111 (1–1)0.057
CD200.2 (0.039–0.97)0.0460.5 (0.23–1.1)0.087
NKp461 (0.82–1.2)0.980.91 (0.73–1.1)0.42